Rationale and design of a randomized clinical trial to compare two antithrombotic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. apixaban (ADALA study)-Reference-Cited by-同舟云学术

Rationale and design of a randomized clinical trial to compare two antithrombotic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. apixaban (ADALA study)

Published:2020-09-28 Issue:2 Volume:59 Page:471-477
ISSN:1383-875X
Container-title:Journal of Interventional Cardiac Electrophysiology
language:en
Short-container-title:J Interv Card Electrophysiol

Author:

Flores-Umanzor Eduardo Josué,Cepas-Guillen Pedro L.,Arzamendi Dabit,Cruz-González Ignacio,Regueiro Ander,Freixa Xavier

Funder

Sociedad Española de Cardiología

NewBristol Myers Squibb/Pfizer Alliance, within the European Thrombosis Investigator-Initiated Research Program

Publisher

Springer Science and Business Media LLC

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10840-020-00884-x.pdf

Reference33 articles.

1. GYH L, Collet JP, Caterina R, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardi-ology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace. 2017;19:1757–8.

2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

3. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.

4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

5. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS);European Heart Journal;2024-08-30

2. Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion;JAMA Cardiology;2024-08-07

3. Early and late hospital readmissions after percutaneous left atrial appendage closure;Revista Española de Cardiología (English Edition);2024-08

4. Short-term antithrombotic strategies after left atrial appendage occlusion: a systematic review and network meta-analysis;Frontiers in Pharmacology;2023-09-01

5. Der interventionelle Vorhofohrverschluss: eine Alternative zur oralen Antikoagulation;Aktuelle Kardiologie;2022-12